background

background

NEWS

18 March 2021

Akston Biosciences and Biolexis Enter COVID-19 Vaccine Partnership

Akston Biosciences and Biolexis Enter COVID-19 Vaccine Partnership

9 February 2021

Akston Biosciences Completes Second Licensing and Supply Agreement with Dechra Pharmaceuticals PLC

Akston Biosciences Completes Second Licensing and Supply Agreement with Dechra Pharmaceuticals PLC

16 January 2021

Disrupting Insulin and IGF Receptor Function in Cancer

Disrupting Insulin and IGF Receptor Function in Cancer

5 January 2021

Akston and LakePharma Announce Strategic Partnership to Manufacture AKS-452

Akston and LakePharma Announce Strategic Partnership to Manufacture AKS-452

1 September 2020

TRACER to support Akston Biosciences’ Phase 1 clinical study of AKS-452

TRACER to support Akston Biosciences’ Phase 1 clinical study of AKS-452

22 July 2020

Akston Biosciences Receives $2.5M Milestone Payment

Akston Biosciences Receives $2.5M Milestone Payment

27 May 2020

Akston Biosciences Awarded NIDDK Phase IIb Grant

Akston Biosciences Awarded NIDDK Phase IIb Grant

9 April 2020

Akston Biosciences Completes Series E Preferred Stock Financing

Akston Biosciences Completes Series E Preferred Stock Financing

15 February 2020

Abstract P1-21-05: A novel long-acting insulin for cancer therapy reduces xenograft tumor growth

Abstract P1-21-05: A novel long-acting insulin for cancer therapy reduces xenograft tumor growth

2 August 2019

Akston Biosciences Completes Licensing and Supply Agreement with Dechra Pharmaceuticals PLC

Akston Biosciences Completes Licensing and Supply Agreement with Dechra Pharmaceuticals PLC

Previous

Dots

Next